EP3124023B1 - Haltbare zubereitung von injizierbarem melatonin mit langzeitstabilität - Google Patents

Haltbare zubereitung von injizierbarem melatonin mit langzeitstabilität Download PDF

Info

Publication number
EP3124023B1
EP3124023B1 EP15769253.4A EP15769253A EP3124023B1 EP 3124023 B1 EP3124023 B1 EP 3124023B1 EP 15769253 A EP15769253 A EP 15769253A EP 3124023 B1 EP3124023 B1 EP 3124023B1
Authority
EP
European Patent Office
Prior art keywords
melatonin
treatment
group
composition
total
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP15769253.4A
Other languages
English (en)
French (fr)
Other versions
EP3124023C0 (de
EP3124023A1 (de
EP3124023A4 (de
Inventor
Darío ACUÑA CASTROVIEJO
Germaine Escames Rosa
Pablo BUENO LARAÑO
Alfonso MANSILLA ROSELLÓ
José Antonio FERRÓN ORIHUELA
José Jorge HERNÁNDEZ MAGDALENA
Miguel Ángel CALLEJA HERNÁNDEZ
Desirée GONZÁLEZ CALLEJAS
Ana Comino Pardo
Carmen OLMEDO MARTÍN
Carmen VENEGAS MALDONADO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad de Granada
Servicio Andaluz de Salud
Original Assignee
Universidad de Granada
Servicio Andaluz de Salud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad de Granada, Servicio Andaluz de Salud filed Critical Universidad de Granada
Publication of EP3124023A1 publication Critical patent/EP3124023A1/de
Publication of EP3124023A4 publication Critical patent/EP3124023A4/de
Application granted granted Critical
Publication of EP3124023B1 publication Critical patent/EP3124023B1/de
Publication of EP3124023C0 publication Critical patent/EP3124023C0/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Definitions

  • the present invention is comprised in the field of medicine and pharmacy and relates to an injectable composition of melatonin having high stability.
  • the present invention also relates to the use of said composition as a medicinal product and to its use in the treatment of various conditions, such as sepsis for example.
  • Melatonin N-acetyl-5-methoxy-tryptamine
  • pineal gland epiphysis cerebri
  • Its rate of secretion follows a circadian rhythm linked to the light-dark cycle, and it plays a fundamental role in inducing sleep.
  • melatonin plays a fundamental role in inflammatory response regulation, since it acts as a potent scavenger of oxygen free radicals that are generated, for example, during sepsis and the subsequent development of systemic inflammatory response syndrome (SIRS) and the subsequent multiple organ dysfunction syndrome (MODS), which is also known as multiple organ failure; during myocardial infarctions; in mitochondrial damage; in abdominal surgery processes; in pulmonary edema; and in kidney or liver failure.
  • SIRS systemic inflammatory response syndrome
  • MODS multiple organ dysfunction syndrome
  • the authors of the present invention have developed an aqueous melatonin composition exhibiting surprising long-term stability and allowing high concentrations of said water-insoluble active ingredient.
  • the properties of said composition render it useful as an injectable, for example, for the intravenous administration thereof.
  • a first aspect of the invention relates to a pharmaceutically acceptable composition in the form of an injectable solution comprising water or a saline solution, propylene glycol, polyethylene glycol and melatonin or a derivative, salt, prodrug, or solvate thereof, wherein the melatonin is at a concentration of between 0.1 and 30 grams for every 100 ml of the total solution (w/v), wherein the proportion of propylene glycol is comprised between 5 and 50 grams for every 100 ml of the total solution (w/v), wherein the proportion of polyethylene glycol is comprised between 5 and 50 grams for every 100 ml of the total solution (w/v), and wherein the derivative of melatonin is defined according to formula (I), wherein:
  • PEG polyethylene glycol
  • the PEG will preferably have a molecular weight between 200 and 600 atomic mass units (amu), and more preferably of 400 amu (PEG 400).
  • PEG Polyethylene glycol
  • PEG400 can also be described as Macrogol 400 and is found as a component in the pharmaceutical industry in drops, injectable solutions, artificial tears, gelatin capsules, etc.
  • PEG 400 is a colorless viscous liquid with high hygroscopicity close to that of PG, while PEG 6000 is a solid substance with a waxy appearance and low hygroscopicity.
  • the PEG400 LD50 is about 30 g/Kg (oral administration in rats). If the results are extrapolated, for a person weighing 70 kg, the toxic dose would be 2100 g. These characteristics make PEG or macrogol ideal for use as a base material for the solution of the present invention.
  • a second aspect of the invention relates to the use of the composition described in the first aspect of the invention in the production of a medicinal product.
  • Any references in the description to methods of treatment refer to the compounds, pharmaceutical compositions and medicaments of the present invention for use in a method for treatment of the human (or animal) body by therapy.
  • a third aspect of the invention relates to the composition described in the first aspect of the invention for use as a medicinal product or for use in therapy.
  • a fourth aspect of the invention relates to the use of the composition described in the first aspect of the invention in the production of a medicinal product useful in human subjects for the treatment of circadian rhythm regulation, inflammatory response regulation, the treatment of systemic inflammatory response syndrome (SIRS), the treatment of multiple organ dysfunction syndrome (MODS), the treatment of sepsis in newborns and children; the treatment of sepsis in adults, the treatment of myocardial infarctions, the treatment of mitochondrial damage, the treatment of pulmonary edema, the treatment of kidney or liver failure, or the treatment of an oxidative stress situation generated during surgery, and particularly during abdominal surgery.
  • SIRS systemic inflammatory response syndrome
  • MODS multiple organ dysfunction syndrome
  • An alternative aspect with respect to the fourth aspect of the invention relates to the composition described in the first aspect of the invention for the treatment in a human subject of circadian rhythm regulation, inflammatory response regulation, the treatment of systemic inflammatory response syndrome (SIRS), the treatment of multiple organ dysfunction syndrome (MODS), the treatment of sepsis in newborns and children; the treatment of sepsis in adults, the treatment of myocardial infarctions, the treatment of mitochondrial damage, the treatment of pulmonary edema, the treatment of kidney or liver failure, or the treatment of an oxidative stress situation generated during surgery, and particularly during abdominal surgery.
  • SIRS systemic inflammatory response syndrome
  • MODS multiple organ dysfunction syndrome
  • an adult human is considered to be patient that is 18 years old or older.
  • a newborn is generally considered to be a patient between 0 and 27 days old, a baby between 28 days and 23 months old, a child from 24 months to 11 years old, and an adolescent from 12 to 17 years old.
  • weight and dose said correlation is not always linear and must be identified for each group of patients.
  • compositions of the invention are prepared using standard methods such as those described or those that are referred to in the Spanish and U.S. Pharmacopoeias and similar reference texts.
  • a fifth aspect relates to the preparation of the composition of the invention, which comprises mixing water, propylene glycol, polyethylene glycol and melatonin or a derivative, salt, prodrug, or solvate thereof, their salts, prodrugs, derivatives or solvates.
  • PPG propylene glycol
  • co-solvents many of which are potentially toxic, such as ethanol or NMP
  • PPG alone does not allow the production of melatonin compositions exhibiting long-term stability.
  • the authors of the present invention have discovered how surprisingly PPG complemented with polyethylene glycol allows not only solubilizing melatonin but also producing compositions exhibiting long-term stability.
  • a first aspect of the invention relates to a pharmaceutically acceptable composition in the form of an injectable solution comprising water or a saline solution, propylene glycol, polyethylene glycol and melatonin or a derivative, salt, prodrug, or solvate thereof, wherein the melatonin is at a concentration of between 0.1 and 30 grams for every 100 ml of the total solution (w/v), wherein the proportion of propylene glycol is comprised between 5 and 50 grams for every 100 ml of the total solution (w/v), wherein the proportion of polyethylene glycol is comprised between 5 and 50 grams for every 100 ml of the total solution (w/v), and wherein the derivative of melatonin is defined according to formula (I), wherein:
  • the composition is lyophilized and comprises a suitable proportion of each of the following components: propylene glycol, polyethylene glycol and melatonin or a derivative, salt, prodrug, or solvate thereof, in order to be able to obtain, once rehydrated, any of the injectable compositions defined in the first aspect of the invention.
  • the injectable composition or solution comprises:
  • the composition described in the first aspect of the invention allows surprisingly high loads of melatonin while at the same time being stable as it was found that at relatively low concentrations of propylene glycol (PPG) used in the present invention, melatonin is significantly solubilized, thereby reducing the risk of irritation or pain which can present as a side effect with the administration of PPG at high concentrations. It is therefore possible to administer high doses of melatonin without administering at the same time large amounts of propylene glycol, which can have toxic effects at very high doses, and in any case reducing the risk of side effects.
  • PPG propylene glycol
  • composition of the first aspect of the invention can also comprise other pharmaceutically acceptable excipients.
  • an excipient is considered any component in the composition other than an active ingredient.
  • excipients that can be used in the injectable composition of the composition include antimicrobial preservatives, such as methylparaben, propylparaben; antioxidants, such as sodium metabisulfite, propyl gallate; stabilizing and suspending agents, such as modified soluble or swellable celluloses, for example sodium carboxymethyl cellulose (Aquasorb, Blanose, Nymcel); tonicity agents, such as sodium chloride; or solubilizers, such as propylene glycol or polyethylene glycols.
  • antimicrobial preservatives such as methylparaben, propylparaben
  • antioxidants such as sodium metabisulfite, propyl gallate
  • stabilizing and suspending agents such as modified soluble or swellable celluloses, for example sodium carboxymethyl cellulose (Aquasorb, Blanose, Nymcel
  • a " pharmaceutically acceptable” composition or component thereof indicates that they are physiologically tolerable and the administration thereof entails a low risk of allergies, side effects, adverse events or other similar reactions, such as gastric disorders, dizziness and the like, when administered to a human being.
  • the expression " pharmaceutically acceptable” means that it has been approved by a regulatory agency of the state or federal government or that it is listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, and more particularly in human beings.
  • the composition of the invention is therefore pyrogen-free.
  • composition of the invention includes melatonin, as well as a derivative, a salt, a prodrug or a solvate thereof.
  • pharmaceutically acceptable salts are synthesized from melatonin by means of conventional chemical methods, generally by making it react with a suitable acid in water or in an organic solvent or in a mixture of both.
  • Non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol or acetonitrile are generally preferred.
  • acid addition salts include mineral acid addition salts such as, for example, hydrochloride, hydrobromide, hydroiodide, sulfate, nitrate, phosphate, and organic acid addition salts such as, for example, acetate, maleate, fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, methanesulfonate and p-toluenesulfonate.
  • prodrug is defined herein to mean a chemical compound that has experienced a chemical derivatization, such as a substitution or addition of an additional chemical group to change (for pharmaceutical use) any of its physicochemical properties, such as solubility or bioavailability, for example ester, ether or amide derivatives of an active compound providing the active compound itself after administration to a subject.
  • a chemical derivatization such as a substitution or addition of an additional chemical group to change (for pharmaceutical use) any of its physicochemical properties, such as solubility or bioavailability, for example ester, ether or amide derivatives of an active compound providing the active compound itself after administration to a subject.
  • solubility or bioavailability for example ester, ether or amide derivatives of an active compound providing the active compound itself after administration to a subject.
  • Particularly preferred prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a patient (for example, allowing an orally administered compound to be more readily absorbed into the blood) or that improve the delivery of the original compound to a biological compartment (for example, the brain or lymphatic system) with respect to the original species.
  • solvate must be understood to mean any form of melatonin according to the invention having another molecule (most likely a polar solvent) bound by means of a non-covalent bond.
  • solvates include hydrates and alcoholates, for example methanolates.
  • the preparation of salts, solvates and prodrugs can be carried out by means of methods known in the art. It must be noted that non-pharmaceutically acceptable salts, solvates or prodrugs are also within the scope of the invention since they can be useful in the preparation of pharmaceutically acceptable salts, solvates or prodrugs.
  • the derivative of melatonin is defined according to formula (I), a salt, prodrug or solvate thereof wherein,
  • the composition of the invention is intravenously injectable.
  • a particular aspect includes the presence of a second medicinal product in the composition of the invention.
  • Said second medicinal product can be part of the composition or can be provided as a separate composition for the administration at the same time or at different times.
  • composition of the invention and therefore of melatonin, will depend on various factors, such as the severity of the disorder being treated, the sex, age or weight of the patient, among many others.
  • the composition of the invention can be administered in the range of 0.1 to 1000 mg/kg/day one or more times a day with standard total daily dosages.
  • the present invention relates to the use of melatonin, its salts, prodrugs, derivatives or solvates in the preparation of a medicinal product for the treatment in humans or animals of processes such as sepsis, for the treatment of systemic inflammatory response syndrome (SIRS) or for the treatment of multiple organ dysfunction syndrome (MODS), the treatment of myocardial infarctions, the treatment of mitochondrial damage, the treatment of pulmonary edema, the treatment of kidney or liver failure, or the treatment of a surgery-induced oxidative stress situation.
  • SIRS systemic inflammatory response syndrome
  • MODS multiple organ dysfunction syndrome
  • said use involves the administration of between 5 and 1,000 mg, between 5 and 700 mg, between 5 and 600 mg or between 5 and 300 mg of melatonin every 24 hours.
  • the amount of melatonin administered to a patient is comprised between 30 and 90 mg every 4 hours, preferably between 40 and 70. In a particular embodiment, between 55 and 75 mg of melatonin are administered to the patient every 24 hours.
  • the minimum doses of melatonin would range between 50 and 500 mg/day ( Venegas et al. 2012. J Pineal Res 52:217-227 ).
  • said use involves the administration of at least 300 mg, preferably at least 400 mg and even more preferably of at least 500 mg of melatonin every 24 hours.
  • said use preferably refers to the treatment of sepsis.
  • the administration is performed by perfusion.
  • melatonin, its salts, prodrugs, derivatives or solvates is administered 1, 2, 3, 4, 5 or 6 times or more a day until reaching the required total daily dose.
  • the treatment period can vary according to the patient's progression, and it usually lasts between 1 and 30 days.
  • said sepsis in adults is severe sepsis.
  • SIRS is a generalized inflammatory response of a range of severe clinical injuries. According to the definition agreed on by the American College of Chest Physicians/Society of Critical Care Medicine, this syndrome is clinically recognized by the presence of two or more of the following symptoms (i) to (iv):
  • Sepsis corresponds to SIRS due to a clear focus of infection. Diagnosis thereof requires two or more SIRS criteria and the presence of a clear clinical picture of infection or microbiological studies (the presence of pathogenic microorganisms in normally sterile fluids, more than 100,000 CFU/ml in urine or in quantitative cultures of bronchial secretions). In addition, sepsis is considered severe when it is associated with organ dysfunction, hypoperfusion or hypotension ( ⁇ 90 mm Hg of systolic blood pressure).
  • hypoperfusion can be included but are not limited to lactic acidosis (lactic acid > 3 mmol/l), oliguria (diuresis 50 ⁇ 30 ml/h for 3 hours or 700 ml in 24 hours), coagulopathy (prolongation of the prothrombin time or thrombocytopenia less than 100,000/ml), or an acute change in mental state (agitation, obnubilation).
  • lactic acidosis lactic acid > 3 mmol/l
  • oliguria diuresis 50 ⁇ 30 ml/h for 3 hours or 700 ml in 24 hours
  • coagulopathy prolongation of the prothrombin time or thrombocytopenia less than 100,000/ml
  • an acute change in mental state agitation, obnubilation
  • treatment refers to the administration of a compound or formulation according to the invention to prevent, improve or eradicate the disease or one or more symptoms associated with said disease.
  • Treatment also covers the prevention, improvement or eradication of the physiological sequelae of the disease.
  • the melatonin for the injectable solution was prepared at a concentration of 6 mg/ml in about 20% of propylene glycol and about 30% of polyethylene glycol and with pyrogen-free water in a sufficient amount (API).
  • Table 1 Qualitative and quantitative composition of the tested composition Component Composition (per ml) Function Melatonin 6.0 mg Active ingredient Propylene glycol 200.0 mg Excipient Polyethylene glycol (macrogol) 300.0 mg Excipient Water for injectables Sufficient amount 1 ml Solvent
  • the material used for packaging the composition described in Table 1 were type I glass ampoules (EP) previously sterilized in an oven.
  • the present study is a stability study of the product specified in Table 1 after preparation and over a 6-month period. Three industrial-sized baths each comprising 1,000 ampoules of the product specified in Table 1 were used to that end.
  • Table 2 Long-term stability data containing the solution comprising 6 mg/ml described in Table 1.
  • Solution comprising 6 mg/ml of melatonin for injection in ampoules.
  • Batch size 1,000 ampoules
  • Type of bath Scaled-down batch Manufacturing date: 27/02/2013
  • Product container once closed Type I glass ampoules containing a colorless, clear and particle-free solution.
  • Test conditions Temperature 25°C+/- 2°C Relative Humidity 60% +/- 5%
  • Position of the product right Parameter Technical specifications 0 (2013/03) 3 (2013/06) 6 (2013/06) Appearance of the product Glass ampoule containing a clear, colorless solution. Complies with the technical specification Complies with the technical specification Complies with the technical specification Particle-free.
  • composition of the invention the solution comprising 6 mg/ml of melatonin for injection in ampoules described in Example 1, hereinafter " injectable of melatonin " , was used in a clinical study with 14 septic patients after abdominal surgery randomly distributed into 2 study groups (A and B).
  • Group A corresponds to patients who, in addition to standard treatment, received the injectable of melatonin at a dose of 60 mg/day for 5 days, blood samples being taken daily to perform successive analytical determinations.
  • Treatment group B received standard treatment and placebo, the latter being the same vial with the same excipients but without the melatonin active ingredient; daily blood samples are also obtained from each patient in this group to perform successive analytical determinations.
  • the blood samples are referred to as T0, T1, T2, T3, T4 and T5.
  • the following blood parameters were analyzed for each of the participating patients from these samples: number of leukocytes, number of red blood cells, hemoglobin, hematocrit, percentage of neutrophils, percentage of lymphocytes, and number of platelets.
  • the biochemical parameters determined in each patient participating in the study were: transaminases (GOT and GPT), gamma-glutamyl transferase, creatinine, urea, alkaline phosphatase (ALP) and lactic dehydrogenase (LDH).
  • the blood parameters comprising the number of leukocytes, neutrophils and lymphocytes, as well as the number of platelets, are parameters that are indicative of a septic state.
  • sepsis is known to cause a drop in the percentage of lymphocytes.
  • the determined biochemical parameters are related to liver function, such as:
  • lactate dehydrogenase also called “lactic acid dehydrogenase” (LDH)
  • LDH lactate dehydrogenase
  • LDH LDH
  • blood levels are generally low.
  • tissues become damaged due to a lesion or disease, they release more LDH into the blood stream.
  • the conditions usually causing this increase in the amount of LDH in the blood stream are the following: liver diseases, heart attacks, anemia, muscle trauma, bone fractures, cancer, infections such as meningitis, encephalitis or HIV.
  • Treatment with the injectable of melatonin in septic patients in group A receiving the injectable shows a progressive increase in the percentage of lymphocytes. This increase is statistically significant. These patients also show a statistically significant decline in the percentage of neutrophils. Both the increase in lymphocytes and the decline in neutrophils occur at all times of the study, reaching levels close to normal values in healthy individuals at the end of the study period. This situation entails an immunological recovery in patients receiving treatment with the injectable of melatonin, as the balance between lymphocytes and neutrophils in patients receiving treatment with the injectable is achieved.
  • treatment with the injectable of melatonin does not involve any liver or kidney damage in patients receiving treatment with the injectable.
  • the differences are due to times 4 and 5 with respect to the initial time:
  • the change in GPT levels is not significant in the different measured moments. Nor are the average values statistically significant.
  • alkaline phosphatase The change in alkaline phosphatase is not significant in the different measured moments. Nor are the average values statistically significant.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (12)

  1. Pharmazeutisch akzeptable Zusammensetzung in Form einer injizierbaren Lösung umfassend Wasser oder eine Salzlösung, Propylenglykol, Polyethylenglykol und Melatonin, oder ein Derivat, Salz, Pro-Pharmakon oder Solvat desselben, wobei das Melatonin in einer Konzentration von zwischen 0,1 und 30 Gramm pro 100 ml der Gesamtlösung (Gew./Vol.) ist, wobei der Anteil von Propylenglykol zwischen 5 und 50 Gramm pro 100 ml der Gesamtlösung (Gew./Vol.) liegt, wobei der Anteil von Polyethylenglykol zwischen 5 und 50 Gramm pro 100 ml der Gesamtlösung (Gew./Vol.) liegt, und wobei das Derivat des Melatonins gemäß der Formel (I) definiert wird,
    Figure imgb0005
     in welcher:
    - n eine ganze Zahl ausgewählt aus der Gruppe bestehend aus 1, 2, 3 und 4 ist;
    - R1 und Ra unabhängig aus der Gruppe bestehend aus linearem oder verzweigtem C1-C4-Alkyl ausgewählt werden; und
    - R2 aus der Gruppe bestehend aus Wasserstoff, linearem oder verzweigtem C1-C4-Alkyl, -C(=O)O-Ra und -C(=O)-N(H)-Ra ausgewählt wird, wobei Ra eine lineare oder verzweigte C1-C4-Alkylgruppe ist.
  2. Pharmazeutisch akzeptable Zusammensetzung nach Anspruch 1, wobei das Melatonin in einer Konzentration von 0,6 Gramm pro 100 ml der Gesamtlösung (Gew./Vol.) ist, wobei der Anteil von Propylenglykol 20 Gramm pro 100 ml der Gesamtlösung (Gew./Vol.) ist und wobei der Anteil von Polyethylenglykol 30 Gramm pro 100 ml der Gesamtlösung (Gew./Vol.) ist.
  3. Pharmazeutisch akzeptable Zusammensetzung nach den Ansprüchen 1 oder 2, dadurch gekennzeichnet, dass die genannte Zusammensetzung lyophilisiert ist.
  4. Zusammensetzung nach einem der Ansprüche 1 bis 3, umfassend zusätzliche pharmazeutisch akzeptable Hilfsstoffe.
  5. Zusammensetzung nach einem der Ansprüche 1 bis 4, umfassend einen zweiten Wirkstoff.
  6. Zusammensetzung nach einem der Ansprüche 1 bis 5 in Form einer intravenösen injizierbaren Lösung.
  7. Verwendung der Zusammensetzung nach einem der Ansprüche 1 bis 6 bei der Herstellung eines Arzneimittels.
  8. Zusammensetzung nach einem der Ansprüche 1 bis 6 für deren Verwendung in Therapie.
  9. Zusammensetzung nach einem der Ansprüche 1 bis 6 für deren Verwendung bei der Behandlung in Menschen (Erwachsenen, Kindern und/oder Neugeborenen) oder Tieren der Regulierung des zirkadianen Rhythmus, der Regulierung der Entzündungsreaktion, der Behandlung des systemischen Entzündungsreaktionssyndrom, der Behandlung des Multiorganversagens, der Behandlung der Sepsis, der Behandlung von Myokardinfarkten, der Behandlung von mitochondrialem Schaden, der Behandlung von Lungenödem, der Behandlung von Nieren- oder Leberversagen, oder der Behandlung von chirurgisch induziertem oxidativem Stress.
  10. Zusammensetzung für deren Verwendung nach den Ansprüchen 8 bis 9, wobei die Verabreichung mittels Perfusion durchgeführt wird.
  11. Zusammensetzung für deren Verwendung nach den Ansprüchen 8 bis 9, wobei die Verabreichung in einem Zeitablauf zwischen 1 und 30 Tagen fortgesetzt wird.
  12. Verfahren zur Zubereitung der pharmazeutisch akzeptablen injizierbaren Zusammensetzung nach einem der Ansprüche 1 bis 6, welches das Mischen von Wasser, Propylenglykol, Polyethylenglykol und Melatonin, oder einem Derivat, Salz, Pro-Pharmakon, oder Solvat desselben, umfasst.
EP15769253.4A 2014-03-27 2015-03-27 Haltbare zubereitung von injizierbarem melatonin mit langzeitstabilität Active EP3124023B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201430442 2014-03-27
PCT/ES2015/070236 WO2015144965A1 (es) 2014-03-27 2015-03-27 Preparación duradera de inyectable de melatonina estable a largo plazo

Publications (4)

Publication Number Publication Date
EP3124023A1 EP3124023A1 (de) 2017-02-01
EP3124023A4 EP3124023A4 (de) 2017-09-06
EP3124023B1 true EP3124023B1 (de) 2023-08-30
EP3124023C0 EP3124023C0 (de) 2023-08-30

Family

ID=54194008

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15769253.4A Active EP3124023B1 (de) 2014-03-27 2015-03-27 Haltbare zubereitung von injizierbarem melatonin mit langzeitstabilität

Country Status (6)

Country Link
US (1) US11344531B2 (de)
EP (1) EP3124023B1 (de)
CN (2) CN106659711A (de)
BR (1) BR112016022394A2 (de)
ES (1) ES2965521T3 (de)
WO (1) WO2015144965A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2684408B1 (es) 2017-03-31 2019-07-09 Univ Granada Uso de melatonina para el tratamiento de tumores
WO2019038586A1 (en) 2017-08-19 2019-02-28 Ftf Pharma Private Limited PHARMACEUTICAL COMPOSITION OF MELATONIN
GR1009541B (el) * 2018-02-26 2019-06-07 Λαμδα Φαρμακευτικα Εργαστηρια Εφαρμοσμενης Ερευνας & Αναπτυξης Α.Ε. Ποσιμα φαρμακευτικα διαλυματα που περιλαμβανουν μελατονινη
WO2021038601A1 (en) 2019-08-30 2021-03-04 Vijayendrakumar Virendrakumarji Redasani Liquid pharmaceutical compositions of melatonin for oral and parenteral administration
CN110934850B (zh) * 2019-11-18 2021-07-06 中国人民解放军军事科学院军事医学研究院 具有急性抗氧化与低氧响应功能的复合纳米药物颗粒及制备方法
WO2021139872A1 (en) * 2020-01-08 2021-07-15 Worphmed Srl Soluble melatonin tripartate adduct for the prevention and treatment of rare and severe eye sight-threatening conditions and neuro-ophthalmic disorders
WO2021205053A1 (es) * 2020-04-09 2021-10-14 Universidad De Granada Composición inyectable de melatonina para el tratamiento de enfermedades virales
CN112891344A (zh) * 2021-02-18 2021-06-04 安徽医科大学第一附属医院 一种褪黑素在制备治疗自身免疫性前列腺炎药物中的应用、治疗自身免疫性前列腺炎的药物
CN113041241A (zh) * 2021-03-23 2021-06-29 上海市浦东医院（复旦大学附属浦东医院） 褪黑素在制备治疗或预防急性痛风炎症的药物中的应用
EP4186504B1 (de) 2021-11-25 2024-05-29 Alissa Healthcare Research Limited Orale pharmazeutische wässrige lösungen mit melatonin und deren verwendung

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4855305A (en) * 1987-03-23 1989-08-08 Applied Medical Research Compositions and methods of effecting contraception utilizing melatonin
FR2754454B1 (fr) * 1996-10-10 1998-11-27 Oreal Utilisation d'au moins un glycol comme agent de solubilisation de la melatonine dans l'eau et compositions obtenues
EP1701718A4 (de) * 2003-12-23 2009-06-24 Abraxis Bioscience Llc Substitutierte melatonin-derivate, verfahren zu ihrer herstellung und anwendungsverfahren
EP1696959A2 (de) * 2003-12-24 2006-09-06 Sepracor, Inc. Melatonin-kombinationstherapie zur verbesserung der schlafqualität
JP2011502990A (ja) * 2007-11-05 2011-01-27 ボーシュ アンド ローム インコーポレイティド 薬物送達用ビヒクルとしての水非混和性物質
WO2010062153A1 (es) * 2008-11-27 2010-06-03 GARCÍA PÉREZ, Miguel, Ángel Composiciones farmacéuticas que contienen melatonina para tratar quemadura en tejidos y órganos internos causadas por sustancias corrosivas
CN101966167A (zh) 2010-09-16 2011-02-09 杭州海王生物工程有限公司 一种褪黑素软胶囊及其制备方法
ES2392903B1 (es) 2011-05-17 2014-01-17 Servicio Andaluz De Salud Preparación inyectable de melatonina
ITMI20112042A1 (it) * 2011-11-10 2013-05-11 Eratech S R L Polvere da ricostituire prima dell'uso comprendente melatonina e preparazione iniettabile ottenibile da tale polvere.

Also Published As

Publication number Publication date
WO2015144965A1 (es) 2015-10-01
ES2965521T3 (es) 2024-04-15
CN106659711A (zh) 2017-05-10
US11344531B2 (en) 2022-05-31
CN114392228A (zh) 2022-04-26
BR112016022394A2 (pt) 2017-08-15
US20170112810A1 (en) 2017-04-27
EP3124023C0 (de) 2023-08-30
EP3124023A1 (de) 2017-02-01
EP3124023A4 (de) 2017-09-06

Similar Documents

Publication Publication Date Title
EP3124023B1 (de) Haltbare zubereitung von injizierbarem melatonin mit langzeitstabilität
US11890317B2 (en) Cell-protecting composition containing cyclo histidine-proline as active ingredient
US9144568B1 (en) Formulations of bendamustine
EP2943200B1 (de) Stabile parenterale dnj-zusammensetzungen
ES2392903B1 (es) Preparación inyectable de melatonina
EP4331583A1 (de) Blutcarnitin erhöhendes mittel
BR112021009365A2 (pt) formulação de glicocorticoide estável
WO2023288044A1 (en) Method for treating sickle cell disease using quercetin-containing compositions
RU2447886C1 (ru) Препарат для коррекции обменных процессов и повышения естественной резистентности организма животных
RU2760324C1 (ru) Новое применение полоксамера в качестве фармакологически активного вещества
CN114376967A (zh) 一种包括羟氯喹的组合物及其制备和应用
SE2050286A1 (en) Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
EP4134078A1 (de) Injizierbare melatoninzusammensetzung zur behandlung von viruserkrankungen
CN110917209A (zh) 含硒化合物或硒纳米在制备治疗关节炎药物的注射剂或微针中的用途
US20260000668A1 (en) Prevention and treatment of coronavirus infection
RU2484842C2 (ru) Средство, обладающее общеукрепляющим, адаптогенным и препятствующим снижению иммунитета действием, и способ его получения
US20230241218A1 (en) Formulations of bendamustine
EP3527211A1 (de) Pharmazeutische zusammensetzung zur behandlung oder remission von chronischer myelogener leukämie
JP2002538075A (ja) 太りすぎの治療および／または予防のための合成組成物およびその使用

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20161026

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20170809

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/10 20170101ALI20170803BHEP

Ipc: A61P 31/00 20060101ALI20170803BHEP

Ipc: A61K 9/08 20060101ALI20170803BHEP

Ipc: A61K 31/405 20060101AFI20170803BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20191122

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ipc: A61K0009000000

Ref country code: DE

Ref legal event code: R079

Ref document number: 602015085402

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61K0031405000

Ipc: A61K0009000000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20230317

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/00 20060101ALI20230303BHEP

Ipc: A61K 31/4045 20060101ALI20230303BHEP

Ipc: A61K 45/06 20060101ALI20230303BHEP

Ipc: A61K 9/19 20060101ALI20230303BHEP

Ipc: A61K 47/10 20060101ALI20230303BHEP

Ipc: A61K 9/00 20060101AFI20230303BHEP

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

RIN1 Information on inventor provided before grant (corrected)

Inventor name: VENEGAS MALDONADO, CARMEN

Inventor name: OLMEDO MARTIN, CARMEN

Inventor name: COMINO PARDO, ANA

Inventor name: GONZALEZ CALLEJAS, DESIREE

Inventor name: CALLEJA HERNANDEZ, MIGUEL ANGEL

Inventor name: HERNANDEZ MAGDALENA, JOSE JORGE

Inventor name: FERRON ORIHUELA, JOSE ANTONIO

Inventor name: MANSILLA ROSELLO, ALFONSO

Inventor name: BUENO LARANO, PABLO

Inventor name: ESCAMES ROSA, GERMAINE

Inventor name: ACUNA CASTROVIEJO, DARIO

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015085402

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

U01 Request for unitary effect filed

Effective date: 20230929

U07 Unitary effect registered

Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT SE SI

Effective date: 20231009

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231230

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230830

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231130

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231230

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230830

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230830

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2965521

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20240415

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230830

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230830

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230830

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230830

U20 Renewal fee for the european patent with unitary effect paid

Year of fee payment: 10

Effective date: 20240327

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602015085402

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20240603

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230830

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230830

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240327

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240327

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240331

U20 Renewal fee for the european patent with unitary effect paid

Year of fee payment: 11

Effective date: 20250325

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20250402

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20150327

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20150327

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230830

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20260323

Year of fee payment: 12

U20 Renewal fee for the european patent with unitary effect paid

Year of fee payment: 12

Effective date: 20260323